Plasma N-Terminal Pro–Brain Natriuretic Peptide and Adrenomedullin

Am, Richards; Mg, Nicholls; Yandle, Tim G.; Frampton, Christopher; Espiner, E. A.; Jg, Turner; Rc, Buttimore; Jg, Lainchbury; Elliott, J.; Ikram, Hamid; Ig, Crozier; Dw, Smyth

doi:10.1161/01.cir.97.19.1921

Cited by 575 publications

(163 citation statements)

References 28 publications

Supporting

Mentioning

146

Contrasting

Unclassified

Order By: Relevance

“…Other studies have demonstrated a similar pattern of risk for patients with elevated NT-proBNP (5,6,(13)(14)(15)(16)(17)(18). Our study extends these prior findings by demonstrating that, at baseline, 24 h and 72 h, NT-proBNP predicts adverse events independent Other studies have demonstrated that BNP predicts adverse events, particularly sudden cardiac death, in both the postmyocardial infarction (19) and heart failure populations (20).…”

Section: Prognosissupporting

confidence: 84%

“…First, although we have demonstrated that NT-proBNP within the first 72 h has powerful prognostic information after an acute myocardial infarct, it is unclear whether the same relationship will be evident if NT-proBNP is assessed later. However, elevated natriuretic peptides after STEMI have consistently demonstrated a strong, negative prognostic value even up to two years (17). Second, we chose to treat NT-proBNP as a continuous variable and in quartiles rather than use a specified cutpoint as is done elsewhere (15).…”

Section: Limitationsmentioning

confidence: 99%

See 1 more Smart Citation

N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction

Théroux

Chang

Mahaffey

et al. 2006

Canadian Journal of Cardiology

View full text Add to dashboard Cite

Section: Prognosissupporting

confidence: 84%

Section: Limitationsmentioning

confidence: 99%

N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction

Théroux

Chang

Mahaffey

et al. 2006

Canadian Journal of Cardiology

View full text Add to dashboard Cite

“…Circulating levels of the cardiac natriuretic peptides, particularly brain natriuretic peptide (BNP) and the 1-76 amino-acid N-terminal pro-BNP (NT-proBNP), have been identified as robust biochemical markers of heart failure in patients presenting with acute shortness of breath, [1][2][3][4] as prognostic indices for mortality and the development of heart failure following acute myocardial infarction, 5,6 and as potentially useful guides to the intensity of pharmacotherapy in patients with chronic heart failure. 7 Natriuretic peptide levels have been reported also to be higher in patients with hypertension, especially those with left ventricular hypertrophy or dysfunction, than in normotensive subjects.…”

Section: Introductionmentioning

confidence: 99%

Plasma N terminal pro-brain natriuretic peptide levels and its determinants in a multi-ethnic population

et al. 2007

View full text Add to dashboard Cite

This study documents the determinants and plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) among hypertensive and normotensive subjects in a multi-ethnic population in the United Arab Emirates (UAE). We obtained demographic, anthropometric and clinical data, together with fasting NT-proBNP and biochemical indices from 128 hypertensive patients and 138 normotensive subjects matched for age, gender and ethnicity. Plasma NT-proBNP levels were significantly (Po0.001), and several-fold higher among hypertensives (median 5.92, inter quartile range (IQR): 1.79-18.48 pmol/l) than normotensives (median 1.78, IQR: 0.59-4.32 pmol/l) in the total study population, and the same was true for the ethnic groups separately. Similarly, plasma levels of glucose, blood urea nitrogen (BUN) and creatinine, but not insulin, were significantly (Po0.05) higher among hypertensives than normotensives. For all subjects combined, log NT-proBNP correlated positively and significantly with age (Po0.01), log glucose (Po0.05), systolic blood pressure (SBP, Po0.001), log BUN (Po0.001) and log creatinine (Po0.001). Multivariate regression analysis showed that NT-proBNP levels were independently and positively correlated with SBP, age, gender, log BUN, Emirati and South East Asian ethnic groups and inversely associated with current exercise. In conclusion, we found circulating levels of NT-proBNP to be significantly increased in hypertensive versus normotensive subjects in the UAE and independently related to SBP, age, gender, indices of renal function and possibly exercise. Our results further suggest a possible modulating effect of ethnicity on NT-proBNP levels.

show abstract

“…Previous studies in nondiabetic populations have shown that plasma levels of both BNP and NTproBNP facilitate the diagnosis of heart failure. Moreover, these novel risk factors are correlated with functional status in patients with congestive heart failure [13]. Plasma levels of BNP and NT-proBNP also correlate with left ventricular dilatation, remodelling and dysfunction [13][14][15].…”

Section: Discussionmentioning

confidence: 99%

Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria

et al. 2004

View full text Add to dashboard Cite

Aims/hypothesis: We examined whether plasma N-terminal probrain natriuretic peptide (NT-proBNP) predicts cardiovascular outcome in patients with type 2 diabetes. Methods: A total of 160 microalbuminuric type 2 diabetic patients (mean age 55.1 years [SD 7.2], 119 men) were enrolled in the Steno-2 Study examining the effect of multifactorial treatment, and were divided into two groups according to baseline levels of plasma NTproBNP below or above the median for the cohort, which was followed for an average of 7.8 years. Cardiovascular outcome was a composite of cardiovascular mortality, myocardial infarction, stroke, revascularisation procedures in the heart or legs, and amputations. Results: In the whole group, plasma NT-proBNP being above the median was associated with an increased risk of cardiovascular disease during follow-up, with an unadjusted hazard ratio of 4.4 (95% CI 2.3-8.4; p<0.0001). A decrease in plasma NT-proBNP of 10 pg/ml during the first 2 years of intervention was associated with a 1% relative reduction in the primary endpoint (p<0.001). Despite polypharmacological treatment targeting cardiovascular disease, the mean plasma NT-proBNP level increased during followup. Conclusions/interpretation: We conclude that high plasma NT-proBNP is a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria.

show abstract

Plasma N-Terminal Pro–Brain Natriuretic Peptide and Adrenomedullin

Cited by 575 publications

References 28 publications

N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction

N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction

Plasma N terminal pro-brain natriuretic peptide levels and its determinants in a multi-ethnic population

Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria

Contact Info

Product

Resources

About